EA
KROS icon

Emerald Advisers’s Keros Therapeutics KROS Stock Holding History

Emerald Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-244,633
Closed -$3.87M – 259
2024
Q4 		$3.87M Buy
244,633
+89,088
+57% +$4.63M 0.15% 113
2024
Q3 		$9.03M Buy
+155,545
New +$7.68M 0.35% 93

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Emerald Advisers's KROS Position: Q1 2025 in Review

Emerald Advisers sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 244,633 shares — an estimated $3.87M sold.

Emerald Advisers first reported a position in KROS in Q3 2024 and held it in 2 quarters. The position peaked at $9.03M in Q3 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Emerald Advisers reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Emerald Advisers sold 244,633 Keros Therapeutics shares in Q1 2025, an estimated $3.87M.
  • Emerald Advisers first reported a position in Keros Therapeutics in Q3 2024 and held it in 2 quarters.
  • Emerald Advisers's Keros Therapeutics position peaked at $9.03M in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Emerald Advisers's 13F filing for Q1 2025, filed 1 May 2025.